(Canagliflozin + teneligliptin) is a Small Molecule owned by Mitsubishi Tanabe Pharma, and is involved in 6 clinical trials, of which 5 were completed, and 1 is ongoing.

MT-2412 acts as anti diabetic agent. The combination drug candidate acts as low affinity sodium glucose cotransporter (SGLT2) and dipeptidyl peptidase-4 (DPP-4) inhibitor. The SGLT2 in cells lining the proximal tubule mediates the majority of renal glucose reabsorption from the tubular fluid, which normally prevents the loss of glucose in the urine. Canagliflozin by blocking SGLT2 significantly increases the amount of glucose excreted in the urine. The DPP- IV enzyme inactivates incretin hormones, which are involved in the physiologic regulation of glucose homeostasis. Teneligliptin slows the inactivation of incretin hormones and thus increases and prolongs their action which in turn increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.

The revenue for (Canagliflozin + teneligliptin) is expected to reach a total of $1.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Canagliflozin + teneligliptin) NPV Report.

(Canagliflozin + teneligliptin) is currently owned by Mitsubishi Tanabe Pharma. Daiichi Sankyo is the other company associated in development or marketing of (Canagliflozin + teneligliptin).

(Canagliflozin + teneligliptin) Overview

Canagliflozin and teneligliptin (Canalia, MT-2412) is a fixed dose combination acts as anti hyperglycemic agent. It is formulated as film coated tablets for oral route of administration. Canalia is indicated for the treatment of type 2 diabetes.

Daiichi Sankyo Overview

Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY1,044,892 million for the fiscal year ended March 2022 (FY2022), an increase of 8.6% over FY2021. In FY2022, the company’s operating margin was 7.1%, compared to an operating margin of 7% in FY2021. In FY2022, the company recorded a net margin of 6.4%, compared to a net margin of 7.9% in FY2021. The company reported revenues of JPY327,480 million for the second quarter ended September 2022, an increase of 16.8% over the previous quarter.

Quick View – (Canagliflozin + teneligliptin)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Canagliflozin + teneligliptin)
Administration Pathway
  • Oral
Therapeutic Areas
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.